To Make the Case--Evidence Is Required Comment on "Making the Case for Selective Use of Statins in the Primary Prevention Setting" Rita F. Redberg, MD, MSc, Editor; Mitchell Katz, MD; Deborah Grady, MD, MPH Arch Intern Med. 2011;171(17):1594.
3) www.ncbi.nlm.nih.gov/pubmed/19263395
Martinez-Carpio PA, et al. Relation between cholesterol levels and neuropsychiatric disorders. Rev Neurol 2009;48(5):261-4 Rev Neurol. 2009 Mar 1-15;48(5):261-4. [Relation between cholesterol levels and neuropsychiatric disorders]. [Article in Spanish] Martà nez-Carpio PA, Barba J, Bedoya-Del Campillo A. Source Centro Penitenciario de Jà ³venes de Barcelona, Generalitat de Catalunya, Sant Joan de Dà ©u, Barcelona, Espaà ±a.
4) Krumholz HM, et al.
http://www.ncbi.nlm.nih.gov/pubmed/7772105
Lack of association between cholesterol and coronary heart disease mortality and morbidity and all-cause mortality in persons older than 70 years. JAMA 1994;272(17):1335-40
5) http://www.ncbi.nlm.nih.gov/pubmed/11502313
Schatz IJ, et al. Cholesterol and all-cause mortality in elderly people from the Honolulu Heart Program: a cohort study. Lancet 2001;358(9279):351-5.
Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trial by Prof James Shepherd MD et al. on behalf of the PROSPER study group
7) healthandpharma.awardspace.com/Week%204%20Readings/Mangin%20Preventitive%20Health%20Care.pdf
Preventive health care in elderly people needs rethinking
BMJ 2007;335:285 Dee Mangin senior lecturer in general practice, Christ church School of Medicine, University of Otago, Christ church, New Zealand
8) http://www.ncbi.nlm.nih.gov/pubmed/15138247
JAMA. 2004 May 12;291(18):2243-52. Drug treatment of hyperlipidemia in women.Walsh JM, Pignone M. Division of General Internal Medicine and Department of Epidemiology and Biostatistics, University of California, San Francisco, USA.
9) http://archinte.ama-assn.org/cgi/content/short/170/12/1024
Statins and All-Cause Mortality in High-Risk Primary Prevention
A Meta-analysis of 11 Randomized Controlled Trials Involving 65 229 Participants. Kausik K. Ray, MD, MPhil, FACC, FESC; Sreenivasa Rao Kondapally Seshasai, MD, MPhil; Sebhat Erqou, MD, MPhil, PhD; Peter Sever, PhD, FRCP, FESC; J. Wouter Jukema, MD, PhD; Ian Ford, PhD; Naveed Sattar, FRCPath Arch Intern Med. 2010;170(12):1024-1031.
10) www.ti.ubc.ca/pages/letter48.htm
Therapeutics Letter, issue 48, April - June 2003
Do Statins have a Role in Primary Prevention? Therapeutics Initiative 2176 Health Sciences Mall Vancouver, BC, Canada
11) blog.drsinatra.com/blog/heart-health-nutrition/new-fda-statin-warning
The FDA Finally Acknowledged Statins Can Cause Diabetes and Memory Loss Wednesday, February 29, 2012 by Stephen Sinatra
12) http://www.ncbi.nlm.nih.gov/pubmed/7572690
Am J Cardiol. 1995 Sep 28;76(9):64C-68C.
Reducing the risk of coronary events: evidence from the Scandinavian Simvastatin Survival Study (4S). Kjekshus J, Pedersen TR. National Hospital, Department of Medicine, Oslo, Norway.
13) http://www.ncbi.nlm.nih.gov/pubmed/9576425
Circulation. 1998 Apr 21;97(15):1453-60.
Lipoprotein changes and reduction in the incidence of major coronary heart disease events in the Scandinavian Simvastatin Survival Study (4S) Pedersen TR, Olsson AG, Faergeman O, Kjekshus J, Wedel H, Berg K, Wilhelmsen L, Haghfelt T, Thorgeirsson G, Pyà ¶rà ¤là ¤ K, Miettinen T, Christophersen B, Tobert JA, Musliner TA, Cook TJ. Aker Hospital, Oslo, Norway.
14) LIPID STUDY
http://www.nejm.org/doi/full/10.1056/NEJM199811053391902
Prevention of Cardiovascular Events and Death with Pravastatin in Patients with Coronary Heart Disease and a Broad Range of Initial Cholesterol Levels, The Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group
N Engl J Med 1998; 339:1349-1357November 5, 1998
15) http://cdn.intechweb.org/pdfs/18255.pdf
Ultrasound Imaging - Medical Applications, ISBN: 978-953-307-279-1
Atherosclerotic Plaque Regression and Arterial Reverse Remodelling in Carotid and Femoral Arteries by Statin Use in Primary Prevention Setting: Ultrasound Findings
By Cesare Rusconi, Riccardo Raddino, Eleftheria Trichaki and Livio Dei Cas
16) www.ncbi.nlm.nih.gov/pubmed/12196332 circ.ahajournals.org/content/106/9/1077.long Circulation. 2002 Aug 27;106(9):1077-82. Influence of lipid-lowering therapy on the progression of coronary artery calcification: a prospective evaluation.
Achenbach S, Ropers D, Pohle K, Leber A, Thilo C, Knez A, Menendez T, Maeffert R, Kusus M, Regenfus M, Bickel A, Haberl R, Steinbeck G, Moshage W, Daniel WG. Source Department of Internal Medicine II, University of Erlangen-NÃ ¼rnberg, Germany.
17) www.ncbi.nlm.nih.gov/pubmed/9869668
N Engl J Med. 1998 Dec 31;339(27):1972-8.
Effect of HMG-CoA reductase inhibitors on coronary artery disease as assessed by electron-beam computed tomography.
Callister TQ, Raggi P, Cooil B, Lippolis NJ, Russo DJ. Source Electron Beam Tomography Research Foundation, Hendersonville, TN 37075, USA.
18) www.ncbi.nlm.nih.gov/pubmed/12888149
Am J Cardiol. 2003 Aug 1;92(3):334-6.
Relation of aggressiveness of lipid-lowering treatment to changes in calcified plaque burden by electron beam tomography. Hecht HS, Harman SM. Source Beth Israel Medical Center, New York,
Next Page 1 | 2 | 3 | 4 | 5 | 6 | 7
(Note: You can view every article as one long page if you sign up as an Advocate Member, or higher).
